The preliminary results of a clinical trial for a disease of "premature aging" - Hutchinson-Gilford Progeria Syndrome (HGPS) - are hopeful and inspiring. However, they cannot directly inform the development of rejuvenation biotechnologies; although the symptoms of HGPS are similar to those observed in aging, there is no evidence to suggest that the underlying mechanism is pathologically significant in those not afflicted with the disease.
The University of Delaware's Socratic Club will be hosting Dr. Aubrey de Grey on Tuesday, October 2.
Reto Hoehner, a SENS Research Foundation volunteer, discusses his work in getting a second-hand Biomek 2000 - a high-throughput PCR automation robot - up and running at our Research Center in Mountain View, and goes on to discuss some use cases and limitations of the hardware.
In early March, the microglia project started when the Academic Inititiative awarded me a small grant to begin setting up functional assays for microglia. I've attached that grant and listed the background information section, without citations, below.
Microglia make up about 5-12% of total brain cells and act as the main immune cells of the CNS, but their function becomes increasingly impaired with age. In July two of the summer interns, Connie Wang and Jennie Sims, submitted a grant proposal that would continue to develop a project to assess exactly what changes occur in aging microglia.
Your vote could mean $10,000 or more for SENS Foundation to put toward our groundbreaking research into effectively mitigating age-related disease. To vote, simply visit SENS Foundation's official Chase Community Giving page.
The final lectures for the Academic Initiative's open online course were filmed yesterday, on-site at the SENS Foundation Research Center in Mountain View, CA. A very considerable amount of editing work remains to be done, but once that work is complete and the videos are prepared, we will post them on the Academic Initiative's website.
This month, a paper reporting results from the LysoSENS project that SENS Foundation funds at Rice University will be published in the printed edition of Biotechnology and Bioengineering. The research that produced these results was primarily performed by Dr. Jacques Mathieu, and focused on identifying enzymes that can degrade or modify 7-ketocholesterol, a root cause of atherosclerosis; such enzymes could ultimately be used as a new class of regenerative therapies to prevent and reverse heart disease.